Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dendreon Readies For Next Provenge Hurdles: Supply And Reimbursement

Executive Summary

Having gotten over the hurdle of FDA approval with the market's first therapeutic cancer vaccine, Dendreon now faces the challenge of getting Provenge to the market. Already the company is also signaling that supply is unlikely to match demand in the near term

You may also be interested in...

Provenge Outcomes Data "Moderately" Strong For Labeled Use; Off-Label Insufficient, AHRQ Tech Assessment Says

Clinical research demonstrating positive health outcomes from Dendreon's prostate cancer vaccine Provenge is "moderately" strong, the Agency for Healthcare Research and Quality concludes in a draft technology assessment prepared for the upcoming meeting of the Medicare Evidence Development and Coverage Advisory Committee.

Dendreon Extends Provenge Supply In Agreement With GSK

Supply arrangement won't impact availability of Provenge this year; first shipment from GSK will begin in 2011, according to a regulatory filing.

Provenge Off-Label Use Is Key CMS Concern In NCA, Dendreon Says

In its ongoing national coverage analysis of Dendreon's Provenge (sipuleucel-T), the Centers for Medicare and Medicaid Services is taking a close look at Medicare coverage for off-label use of the novel prostate cancer vaccine, according to the company

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts